Supplementation with two probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 649-656

  Ahn, Hyeon Yeong ^a   Kim, Minjoo ^a   Chae, Jey Sook ^a   Ahn, Young Tae ^b   Sim, Jae Hun ^b   Choi, Il Dong ^b   Lee, Sang Hyun ^c   Lee, Jong Ho ^a,d  

^a Yonsei University   (South Korea)

^b Korea Yakult Co   (South Korea)

^c National Health Insurance Corporation   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Apolipoprotein A V; Hypertriglyceridemic; LDL particle size; Probiotic; Triglyceride

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A5; C PEPTIDE; C REACTIVE PROTEIN; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROBIOTIC AGENT; TRIACYLGLYCEROL; APOA5 PROTEIN, HUMAN; APOLIPOPROTEIN A; GLUCOSE BLOOD LEVEL; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; LACTOBACILLUS CURVATUS; LACTOBACILLUS CURVATUS HY7601; LACTOBACILLUS PLANTARUM; LACTOBACILLUS PLANTARUM KY1032; LIPID ACCUMULATION PRODUCT INDEX; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SUPPLEMENTATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO; ANALYSIS; ANTHROPOMETRY; BLOOD; CHEMISTRY; COHORT ANALYSIS; DIETARY SUPPLEMENT; GENETICS; GENOTYPE; LACTOBACILLUS; MICROBIOLOGY;

ANTHROPOMETRY; APOLIPOPROTEINS A; BLOOD GLUCOSE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; COHORT STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; GENOTYPE; HUMANS; HYPERTRIGLYCERIDEMIA; LACTOBACILLUS; LACTOBACILLUS PLANTARUM; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; PROBIOTICS; TRIGLYCERIDES;

EID: 84932643723     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.06.030     Document Type: Article

References (35)

1. Le N.A., Walter M.F. The role of hypertriglyceridemia in atherosclerosis. Curr. Atheroscler. Rep. 2007, 9:110-115.
2. Jang Y.S., Chae J.S., Kim O.Y., Park H.J., et al. APOA5-1131T>C genotype effects on apolipoprotein A5 and triglyceride levels in response to dietary intervention and regular exercise (DIRE) in hypertriglyceridemic subjects. Atherosclerosis 2010, 211:512-519.
3. Chug H.K., Chae J.S., Hyun Y.J., Paik J.K., et al. Influence of adiponectin gene polymorphisms on adiponectin level and insulin resistance index in response to dietary intervention in overweight-obese patients with impaired fasting glucose or newly diagnosed type 2 diabetes. Diabetes Care 2009, 32:552-558.
4. Zhan S., Ho S.C. Meta-analysis of the effects of soy protein containing isoflavones on the lipid profile. Am. J. Clin. Nutr. 2005, 81:379-408.
5. Moroti C., Magri L.F., Costa M.D., Cavallini D.C., et al. Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012, 11:29.
6. Andrade S., Borges N. Effect of fermented milk containing Lactobacillus acidophilus and Bifidobacterium longum on plasma lipids of women with normal or moderately elevated cholesterol. J.Dairy Res. 2009, 76:469-474.
7. Ataie-Jafari A., Larijani B., Majd H.A., Tahbaz F. Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects. Ann. Nutr. Metab. 2009, 54:22-27.
8. Fuentes M.C., Lajo T., Carrión J.M., Cuñé J. Cholesterol-lowering efficacy of Lactobacillus plantarum CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. Br. J. Nutr. 2013, 109:1866-1872.
9. Miremadi F., Ayyash M., Sherkat F., Stojanovska L. Cholesterol reduction mechanisms and fatty acid composition of cellular membranes of probiotic Lactobacilli and Bifidobacteria. J.Funct. Foods 2014, 9:295-305.
10. Park D.Y., Ahn Y.T., Huh C.S., McGregor R.A., et al. Dual probiotic strains suppress high fructose-induced metabolic syndrome. World J. Gastroenterol. 2013, 19:274-283.
11. Hyun Y.J., Jang Y., Chae J.S., Kim J.Y., et al. Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men. Atherosclerosis 2009, 205:568-573.
12. The Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
13. Kahn H.S. The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc. Disord. 2005, 5:26.
14. Kim J.Y., Kim O.Y., Paik J.K., Lee S.H., et al. Association of apolipoprotein A-V concentration with apolipoprotein A5 gene -1131T>C polymorphism and fasting triglyceride levels. J.Clin. Lipidol. 2013, 7:94-101.
15. Xiao J.Z., Kondo S., Takahashi N., Miyaji K., et al. Effects of milk products fermented by Bifidobacterium longum on blood lipids in rats and healthy adult male volunteers. J.Dairy Sci. 2003, 86:2452-2461.
16. Hlivak P., Odraska J., Ferencik M., Ebringer L., et al. One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. Bratisl. Lek. Listy 2005, 106:67-72.
17. Ashar M.N., Prajapati J.B. Verification of hypocholesterolemic effect of fermented milk on human subjects with different cholesterol levels. Folia. Microbiol. (Praha) 2000, 45:263-268.
18. Guo Z., Liu X.M., Zhang Q.X., Shen Z., et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr. Metab. Cardiovasc. Dis. 2011, 21:844-850.
19. Lewis S.J., Burmeister S. Adouble-blind placebo-controlled study of the effects of Lactobacillus acidophilus on plasma lipids. Eur. J. Clin. Nutr. 2005, 59:776-780.
20. Greany K.A., Bonorden M.J., Hamilton-Reeves J.M., McMullen M.H., et al. Probiotic capsules do not lower plasma lipids in young women and men. Eur. J. Clin. Nutr. 2008, 62:232-237.
21. Park D.Y., Ahn Y.T., Huh C.S., Jeon S.M., et al. The inhibitory effect of Lactobacillus plantarum KY1032 cell extract on the adipogenesis of 3T3-L1 cells. J.Med. Food 2011, 14:670-675.
22. Pennacchio L.A., Olivier M., Hubacek J.A., Cohen J.C., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 2001, 294:169-173.
23. Fruchart-Najib J., Baugé E., Niculescu L.S., Pham T., et al. Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem. Biophys. Res. Commun. 2004, 319:397-404.
24. Marçais C., Verges B., Charrière S., Pruneta V., et al. Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J.Clin. Invest. 2005, 115:2862-2869.
25. Schaap F.G., Rensen P.C., Voshol P.J., Vrins C., et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J.Biol. Chem. 2004, 279:27941-27947.
26. Mattei J., Demissie S., Tucker K.L., Ordovas J.M. Apolipoprotein A5 polymorphisms interact with total dietary fat intake in association with markers of metabolic syndrome in Puerto Rican older adults. J.Nutr. 2009, 139:2301-2308.
27. Lai C.Q., Corella D., Demissie S., Cupples L.A., et al. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham heart study. Circulation 2006, 113:2062-2070.
28. Kang R., Kim M., Chae J.S., Lee S.H., et al. Consumption of whole grains and legumes modulates the genetic effect of the APOA5 -1131C variant on changes in triglyceride and apolipoprotein A-V concentrations in patients with impaired fasting glucose or newly diagnosed type 2 diabetes. Trials 2014, 15:100.
29. Kim M., Chae J.S., Kim M., Lee S.H., et al. Effects of a 3-year dietary intervention on age-related changes in triglyceride and apolipoprotein A-V levels in patients with impaired fasting glucose or new-onset type 2 diabetes as a function of the APOA5 -1131 T > C polymorphism. Nutr. J. 2014, 13:40.
30. Oliva C.P., Carubbi F., Schaap F.G., Bertolini S., et al. Hypertriglyceridaemia and low plasma HDL in a patient with apolipoprotein A-V deficiency due to a novel mutation in the APOA5 gene. J.Intern. Med. 2008, 263:450-458.
31. Grosskopf I., Baroukh N., Lee S.J., Kamari Y., et al. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler. Thromb. Vasc. Biol. 2005, 25:2573-2579.
32. Carmena R., Duriez P., Fruchart J.C. Atherogenic lipoprotein particles in atherosclerosis. Circulation 2004, 109(Suppl.1):III2-7.
33. Taverna M.J., Martínez-Larrad M.T., Frechtel G.D., Serrano-Ríos M. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur. J. Endocrinol. 2011, 164:559-567.
34. Kahn H.S. The lipid accumulation product is better than BMI for identifying diabetes: a population-based comparison. Diabetes Care 2006, 29:151-153.
35. Rimm E.B., Giovannucci E.L., Stampfer M.J., Colditz G.A., et al. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am. J. Epidemiol. 1992, 135:1114-1126.